ClinicalTrials.gg
CompletedNCT03300583Updated Feb 21, 2021

Toward Self-management in ILD

An observational study in Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis and Connective Tissue Related ILD, sponsored by Kingston University. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-21.

Primary conditionIdiopathic Pulmonary FibrosisRegistry: Lung Diseases, InterstitialReclassifiedWhy we changed it
Registry
Lung Diseases, Interstitial — the first condition term the registry derived for this study.
ClinicalTrials.gg
Idiopathic Pulmonary Fibrosis
Why
  1. The study's listed conditions name Idiopathic Pulmonary Fibrosis, a narrower term within Lung Diseases, Interstitial.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Kingston University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
18 Years and older
Sex
All
01

Study summary

Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to choose healthier options and also transform the relationship between service user and caregivers from one in which the former is a passive recipient of care to one in which they are an active partner in decision-making.

Interstitial lung disease (ILD) is one such long term condition. Patients with ILD often express concern about the lack of information on possible rehabilitation programmes and other services that could potentially improve self-management of the disease. In addition, there is a general perception about a lack of co-ordination between health care professionals especially in relation to referral to services for comprehensive management of the disease. Therefore, the needs of patients with ILD and their carers, and possible gaps in service provision need to be explored further.

In this study, the investigators propose to explore the needs of ILD patients from all types of ILD and all stages of severity and to also involve carers and clinicians. The investigators will conduct three focus groups for patients and carers and six one-to-one interviews with clinicians to explore perceptions about service gaps and needs in two ILD centres in South and North London, UK.

This study will provide valuable information to develop the building blocks of a self-management resource and will enable the investigators to make it specific to the different types of ILD.

02

Conditions studied

  • Interstitial Lung Disease
  • Idiopathic Pulmonary Fibrosis
  • Connective Tissue Related ILD
  • Chronic Hypersensitivity Pneumonitis
  • Fibrotic Lung Disease

Browse trials for

Keywords

  • Interstitial lung disease
  • Self-Management
  • Service provision
03

In context

Idiopathic Pulmonary Fibrosis Reclassified

576 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 123 are open to participants now.

This study's enrollment of 16 is below the median of 152 across 165 observational studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

Kingston University is the lead sponsor of 8 studies on the registry; none are open to participants now.

Compared within Idiopathic Pulmonary Fibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Interstitial. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with Interstitial Lung disease (ILD), their carers and healthcare professionals involved in their care in two hospitals in South and North London, UK.

Eligibility criteria

PATIENTS

Inclusion Criteria:

  • Diagnosed with Interstitial Lung disease (all types apart from sarcoidosis)
  • Age >18 years
  • At least one consultation with a health care professional

Exclusion Criteria:

  • Diagnosed with sarcoidosis
  • Unable to communicate in English
  • Severity of condition and commodities preventing participation

CAREGIVERS

Inclusion Criteria:

  • Currently caring for a participant with ILD

Exclusion Criteria:

  • Unable to communicate in English

CLINICIANS:

Inclusion Criteria:

  • Involved in the clinical management and treatment of ILD patients

Exclusion Criteria:

  • Health care professionals not directly involved in management or treatment of ILD patients
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (actual)
Patient registry
No

Groups and cohorts

  • ILD patients

    Patients from all types of ILD who are under the care of the two collaborating hospitals.

    Behavioral: Focus groups

  • Family/Carers

    Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.

    Behavioral: Focus groups

  • Clinicians

    Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.

    Behavioral: Semi-structured interviews

Interventions

  • BehavioralFocus groups

    Focus group discussion led by the PI and facilitated by another researcher.

  • BehavioralSemi-structured interviews

    1:1 semi-structured interviews led by the PI

06

What researchers measure

Primary outcomes

  1. Perceptions of service needs and gaps in current services among ILD patients, carers and clinicians

    Exploratory method, conducted using semi-structured 1:1 interviews and focus groups

    Time frame: 1-2 hours

Secondary outcomes

  1. Differences in perceptions between participating ILD patients, carers and clinicians

    Exploratory method, conducted using semi-structured interviews and focus groups

    Time frame: 1-2 hours

  2. Presentation and explanation of diagnosis and its implications to ILD patients and carers

    Exploratory method using semi-structured interviews and focus groups

    Time frame: 1-2 hours

  3. Presentation and explanation of information about the management of the disease to ILD patients and carers

    Exploratory method using semi-structured interviews and focus groups

    Time frame: 1-2 hours

  4. Recommended solutions for better self-management

    Exploratory method using semi-structured interviews and focus groups

    Time frame: 1-2 hours

07

Study locations

2 sites
  • St George's Hospital London
    London, SW17 ORE, United Kingdom
  • University College Hospital
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — A unique identification number will be allocated to each participant and data will not be shared without being anonymised

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Oct 2020, 28 months.

Of 74 non-industry observational studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 110. This study's 28 months is below that.

Counting every sponsor, half of 88 studies reached it within 54 months; a quarter within 29 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2017
First posted
Oct 3, 2017
StartActual
Jun 1, 2018
Primary completionActual
Oct 30, 2020
CompletionActual
Dec 30, 2020
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03300583
Lead sponsor
Kingston University
Collaborators
St. George's Hospital, London, University College London Hospitals
Responsible party
Dimitra Nikoletou (Associate Professor, Kingston University) — Principal investigator
First posted
Oct 3, 2017
Start date
Jun 1, 2018
Primary completion
Oct 30, 2020
Completion
Dec 30, 2020
Last update
Feb 21, 2021

Study contacts

Dimitra Nikoletou, PhD
principal investigator · Kingston University and St George's University of London- Joint Faculty- Health, Social care and Education

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion